With volume predicted to rise at ASCs the coming decade, it will be important to keep tabs on outcomes and adverse events.

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

By group, procedural success and freedom from LVOT obstruction (LVOT mean gradient > 50 mm Hg), the primary efficacy endpoint ...